AIM2 and cancer: AIM2 was selected because it was previously thought to be a TSG that is frequently hypermethylated in cancer (Figure S8) [25] and because, unlike RUNX3, it becomes unmethylated specifically in the myeloid lineage (Figure 4B,C).